Global Antisense & RNAi Therapeutics Market (2020 to 2030) - Opportunities and Strategies
April 07, 2021 05:23 ET
|
Research and Markets
Dublin, April 07, 2021 (GLOBE NEWSWIRE) -- The "Antisense & RNAi Therapeutics Global Market Opportunities and Strategies to 2030: COVID-19 Growth and Change" report has been added to...
Global Antisense and RNAi Therapeutics Market Report 2021: Market to Reach $1.9 Billion by 2027 - Antisense RNA Segment is Projected to Account for $974.2 Million
March 30, 2021 07:38 ET
|
Research and Markets
Dublin, March 30, 2021 (GLOBE NEWSWIRE) -- The "Antisense and RNAi Therapeutics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global...
Global Viral Vector & Plasmid DNA Manufacturing Market Report 2021 - Rising Use of Viral Vectors in Several Treatments Demands Developments in Plasmids and Vectors
February 17, 2021 05:48 ET
|
Research and Markets
Dublin, Feb. 17, 2021 (GLOBE NEWSWIRE) -- The "Viral Vector & Plasmid DNA Manufacturing Market Research Report by Type, by Workflow, by Application, by End User - Global Forecast to 2025 -...
OliX Pharmaceuticals Announces Results from Preclinical Study of Hair Loss Therapeutic Candidate
February 10, 2021 17:45 ET
|
OliX Pharmaceuticals
Company to discuss study results and present corporate overview at SMi’s 12th Annual RNA Therapeutics Virtual Conference on February 11 SUWON, Republic of Korea, Feb. 10, 2021 (GLOBE NEWSWIRE) --...
Global RNA Interference Drug Delivery Market (2020 to 2025) - Industry Trends, Share, Size, Growth, Opportunity and Forecast
December 21, 2020 06:53 ET
|
Research and Markets
Dublin, Dec. 21, 2020 (GLOBE NEWSWIRE) -- The "RNA Interference (RNAi) Drug Delivery Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to...
NapaJen Pharma Reports Positive Results from Phase 1 Clinical Trial of Novel RNA Interference (RNAi) Therapeutic
October 08, 2020 07:35 ET
|
NapaJen
NJA-730 is an Anti-CD-40 Oligonucleotide Combined with Beta-Glucan Delivery Vehicle with Potential to Treat Acute Graft-versus-Host Disease (aGvHD) Treatment Shown to be Safe and Well-Tolerated...
Global RNAi Technologies, Markets & Companies Report 2020 with Profiles of 167 Companies Along with 229 Collaborations
September 21, 2020 04:13 ET
|
Research and Markets
Dublin, Sept. 21, 2020 (GLOBE NEWSWIRE) -- The "RNAi - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering. The report...
World RNAi Market 2020-2025: Oncology is Expected to Hold Significant Market Share in the Therapeutics Type Area
August 31, 2020 05:44 ET
|
Research and Markets
Dublin, Aug. 31, 2020 (GLOBE NEWSWIRE) -- The "RNA-interference (RNAi) Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering. The...
Global Agricultural Biotechnology Market was Valued at USD 33.8 billion by 2024, Observing a CAGR of 10.9% during 2019–2024: VynZ Research
December 17, 2019 13:35 ET
|
VynZ Research
NEW YORK, Dec. 17, 2019 (GLOBE NEWSWIRE) -- The global agricultural biotechnology market was valued at USD 33.8 billion in 2018 and is expected to grow at a CAGR of 10.9% during the forecast period....
NapaJen Pharma Announces First Patient Dosed in Phase 1 First-in-Human Clinical Trial of Novel RNA Interference (RNAi) Therapeutic
November 15, 2018 07:35 ET
|
NapaJen
NJA-730 is an Anti-CD-40 Small Interfering RNA (siRNA) Combined with Beta-Glucan Delivery Vehicle with Potential to Treat Acute Graft-versus-Host Disease Program Leverages NapaJen’s Immune...